小剂量奎的平作为增效剂治疗难治性抑郁症的疗效观察

被引：20

作者：

朴胜斌

王鹏

张耀文

张文顺

机构：

[1] 广东省深圳市康宁医院,深圳市精神卫生研究所

来源：

精神医学杂志 | 2007年 / 03期

关键词：

奎的平; 增效剂; 难治性抑郁症;

D O I：

暂无

中图分类号：

R749.4 [情感性精神病];

学科分类号：

摘要：

目的探讨小剂量奎的平作为增效剂治疗难治性抑郁症的疗效及安全性。方法26例难治性抑郁症患者在原抗抑郁剂治疗的基础上合用小剂量奎的平。观察时间8周,于治疗前及治疗后1、2、4、8周末采用汉米尔顿抑郁量表、临床总体印象量表—严重程度量表评定疗效,采用副反应量表评定药物不良反应.结果自治疗2周末始,汉米尔顿抑郁量表、临床总体印象量表—严重程度量表评分比治疗前均有减少,差异有显著性。治疗8周末痊愈率11.54%,有效率50.00%,无效率38.46%,不良反应较轻。结论小剂量奎的平可作为增效剂用于难治性抑郁的治疗。

引用

页码：142 / 143+146 +146

页数：3

共 11 条

[1]

Clinical and theoreticalimplication of 5-HT2and DA2receptors occupancy of clozap-ine,risperidone,and olanzapine in schizophrenia. Kapur S,Zipurski RB,Remington G. American Journal of Psychiatry . 1999

[2]

Treatment algorithms intreatment-resistant depression. Amasterdam JD,Hornig-Rohan M. J Psychiatr Clin North Am . 1996

[3]

Mianserin,a 5-HT2a/2c and alpha 2 antagonist,inthe treatment of sexual dysfunction induced by serotonin re-uptake inhibitors. Aizenberg D. Journal of Clinical Neurophysiology . 1997

[4]

Risperidone augmentation of selectivese-rotonin reuptake inhibitors in major depression. Ostroff RB,Nelson JC. Journal of Clinical Psychopharmacology . 1999

[5]

Neurobiology of the obsessive-compulsive spectrumdisorders. Stein DJ. Biological Psychiatry . 2000

[6]

Synergistic effects of olanzapine and other antipsy-chotic agents in combination with fluoxetine on norepinephrineand dopamine releasa in rat prefrontal cortex. Zhang W. J Neuropsy-chopharmacology . 2000

[7]

Reduced brain norep-inephrine and dopamine release in treatment-refractory depres-sive illness:evidence in support of the catechoiamine hypothe-sis of mood disorders. Lambert G,Johansson M,Agren H,et al. J Arch Gen Psychiatry . 2005

[8]

Classification of neuropsychiatric medication byprincipal mechanism of actin:a meaningful way to anticipatepharmacodynamically mediated drug interantion. Preskorn SH. J Psychiat-ric Practice . 2003

[9]

Treatment-risistant depression:definition and treatment approaches. Nierenberg AA,Amsterdam JD. Journal of Clinical Psychiatry . 1990

[10]

The effectiveness of olanzap-ine,risperidone,quetiapine,and ziprasidone as augmentation a-gents in treatment-resistant major depressive disorder. Barbee JG,conrad EJ,Jamhour NJ. Journal of Clinical Psychopharmacology . 2004

← 1 2 →